drugset / Trial / NCT00606814
Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is a Phase I clinical trial of IPI-504 in combination with docetaxel (Taxotere).The purposes of the study are to determine: * the safety profile, * the highest dose of IPI-504 that can be given with docetaxel without causing severe side effects, and * to recommend a Phase II dose of the combination in patients with solid tumors.
Timeline
- Start
- 2007-12
- Primary completion
- 2011-05
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | retaspimycin | Small molecule | 300 mg/m2 | Intravenous |
| Background | Docetaxel | Small molecule | 36 mg/m2 | — |
| Background | Docetaxel | Small molecule | 75 mg/m2 | — |